Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) EBIT: 2012-2016

Historic EBIT for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2016 value amounting to -$58.4 million.

  • Tvardi Therapeutics' EBIT fell 10.05% to -$13.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$67.2 million, marking a year-over-year decrease of 46.74%. This contributed to the annual value of -$58.4 million for FY2016, which is 131.86% down from last year.
  • Latest data reveals that Tvardi Therapeutics reported EBIT of -$58.4 million as of FY2016, which was down 131.86% from -$25.2 million recorded in FY2015.
  • Tvardi Therapeutics' EBIT's 5-year high stood at -$237,000 during FY2013, with a 5-year trough of -$58.4 million in FY2016.
  • For the 3-year period, Tvardi Therapeutics' EBIT averaged around -$33.9 million, with its median value being -$25.2 million (2015).
  • Per our database at Business Quant, Tvardi Therapeutics' EBIT soared by 96.20% in 2013 and then slumped by 7,525.32% in 2014.
  • Tvardi Therapeutics' EBIT (Yearly) stood at -$6.2 million in 2012, then skyrocketed by 96.20% to -$237,000 in 2013, then plummeted by 7,525.32% to -$18.1 million in 2014, then plummeted by 39.38% to -$25.2 million in 2015, then plummeted by 131.86% to -$58.4 million in 2016.